Search

Displaying results 6161 - 6170 of 10000 in total
  1. Drug

    Luveltamab tazevibulin

    go.drugbank.com/drugs/DB17563
    Investigational

    [A257414] It is under investigation in clinical trial NCT05200364 (A Study of STRO-002, an Anti-folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

  2. Drug

    GW 468816

    go.drugbank.com/drugs/DB05417
    Investigational

    It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.

    Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitors
  3. Drug

    Puromycin

    go.drugbank.com/drugs/DB08437
    Experimental

    Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. … Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.

  4. Drug

    IRX-2

    go.drugbank.com/drugs/DB05643
    Investigational

    It is being investigated to promote or enhance an anti-cancer immune response.

  5. Drug

    QXL138AM

    go.drugbank.com/drugs/DB18552
    Investigational

    QXL138AM is a masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a. It binds the CD138 protein on the surface of the tumour cells.

    Synonyms: Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a
  6. Drug

    Me-4(18F)DG

    go.drugbank.com/drugs/DB19207
    Investigational

    Me-4(18F)DG is under investigation in clinical trial NCT05558904 (An Investigational Scan (Me-4fdg PET/CT) for the Detection of Sodium-glucose Transport for Early Diagnosis of Lung Cancer).

  7. Drug

    Atabecestat

    go.drugbank.com/drugs/DB15307
    Investigational

    Atabecestat is under investigation in clinical trial NCT02211079 (A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9,

  8. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

  9. Drug

    Amineptine

    go.drugbank.com/drugs/DB04836
    ApprovedIllicitWithdrawn

    The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until

  10. Drug

    Ulimorelin

    go.drugbank.com/drugs/DB12128
    Investigational

    Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility